219 related articles for article (PubMed ID: 33966430)
1. The need for immunotherapy when neoadjuvant chemoradiotherapy achieves pathologic complete response in stage IIIB non-small cell lung cancer: a case report.
Lv C; Zhao L; Zhu Y; Wang P; Sun Z
Ann Palliat Med; 2021 Apr; 10(4):4965-4969. PubMed ID: 33966430
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
[TBL] [Abstract][Full Text] [Related]
3. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.
Yang CF; Adil SM; Anderson KL; Meyerhoff RR; Turley RS; Hartwig MG; Harpole DH; Tong BC; Onaitis MW; D'Amico TA; Berry MF
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1607-13. PubMed ID: 26719403
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.
Kim HK; Cho JH; Choi YS; Zo JI; Shim YM; Park K; Ahn MJ; Ahn YC; Kim K; Kim J
Lung Cancer; 2016 Jun; 96():56-62. PubMed ID: 27133751
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immunotherapy plus chemotherapy achieved pathologic complete response in stage IIIB lung adenocarcinoma harbored EGFR G779F: a case report.
Wang Y; Yang X; Tian X; Jia Z; Bing Z; Cao L; Gao C; Cao Z; Li S; Liang N
Ann Palliat Med; 2020 Nov; 9(6):4339-4345. PubMed ID: 33183013
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ
Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?
Mirimanoff RO
Chin Clin Oncol; 2015 Dec; 4(4):49. PubMed ID: 26730761
[TBL] [Abstract][Full Text] [Related]
8. Salvage Surgery Post Definitive Chemoradiotherapy and Durvalumab for Lung Cancer.
Minegishi K; Tsubochi H; Ohno K; Komori K; Ozeki M; Endo S
Ann Thorac Surg; 2021 Jul; 112(1):e53-e55. PubMed ID: 33373589
[TBL] [Abstract][Full Text] [Related]
9. Should surgery be part of the multimodality treatment for stage IIIB non-small cell lung cancer?
Collaud S; Provost B; Besse B; Fabre D; Le Chevalier T; Mercier O; Mussot S; Fadel E
J Surg Oncol; 2018 Jun; 117(7):1570-1574. PubMed ID: 29573419
[TBL] [Abstract][Full Text] [Related]
10. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.
Stupp R; Mayer M; Kann R; Weder W; Zouhair A; Betticher DC; Roth AD; Stahel RA; Majno SB; Peters S; Jost L; Furrer M; Thierstein S; Schmid RA; Hsu-Schmitz SF; Mirimanoff RO; Ris HB; Pless M
Lancet Oncol; 2009 Aug; 10(8):785-93. PubMed ID: 19604722
[TBL] [Abstract][Full Text] [Related]
12. Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy.
Li L; Chen T; Lai H; Zhang A; Zhao X; Wu J; Hong H; Wu L; Lin S; Wang K; Zhang H; Fang C
Medicine (Baltimore); 2022 Jun; 101(23):e29336. PubMed ID: 35687776
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
[TBL] [Abstract][Full Text] [Related]
14. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
[TBL] [Abstract][Full Text] [Related]
15. A standardized technique of systematic mediastinal lymph node dissection by video-assisted thoracoscopic surgery (VATS) leads to a high rate of nodal upstaging in early-stage non-small cell lung cancer.
Reichert M; Steiner D; Kerber S; Bender J; Pösentrup B; Hecker A; Bodner J
Surg Endosc; 2016 Mar; 30(3):1119-25. PubMed ID: 26169635
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefit of neoadjuvant chemoradiotherapy for the avoidance of pneumonectomy; assessment in 12 consecutive centrally located non-small cell lung cancers.
Misumi K; Harada H; Tsubokawa N; Tsutani Y; Matsumoto K; Miyata Y; Yamashita Y; Okada M
Gen Thorac Cardiovasc Surg; 2017 Jul; 65(7):392-399. PubMed ID: 28432576
[TBL] [Abstract][Full Text] [Related]
18. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
Xu YP; Li B; Xu XL; Mao WM
Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer.
Shimada Y; Suzuki K; Okada M; Nakayama H; Ito H; Mitsudomi T; Saji H; Takamochi K; Kudo Y; Hattori A; Mimae T; Aokage K; Nishii T; Tsuboi M; Ikeda N
Interact Cardiovasc Thorac Surg; 2016 Dec; 23(6):895-901. PubMed ID: 27543652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
